<DOC>
	<DOC>NCT02317861</DOC>
	<brief_summary>The purpose of this study is to explore the pharmacodynamics (PD), pharmacokinetics (PK), safety, and tolerability of multiple doses of RDEA3170 administered in combination with febuxostat compared to RDEA3170 administered alone and febuxostat administered alone in Japanese adult male subjects with gout or asymptomatic hyperuricemia.</brief_summary>
	<brief_title>A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<mesh_term>Benzbromarone</mesh_term>
	<criteria>Screening serum uric acid level ≥ 8 mg/dL; Body weight ≥ 50 kg and a body mass index (BMI) ≥ 18 and ≤ 40 kg/m2; Free of any clinically significant disease or medical condition, per the Investigator's judgment. History or suspicion of kidney stones; Diagnosis of benign prostatic hypertrophy (BPH) or neurogenic bladder or evidence of BPH/neurogenic bladder such as thin urinary stream or difficulty in urination; An estimated creatinine clearance &lt; 60 mL/min calculated by the CockcroftGault formula; QTcF interval (QT interval corrected for heart rate using Fridericia's formula) &gt; 450 msec at Screening; Receiving strong or moderate Cytochrome P450 (CYP) 3A inhibitors or pglycoprotein inhibitors, or digoxin</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>